$40.8 million in cash and cash equivalents as of September 30, 2023; expected runway into the second half of 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASLN:
- ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Aslan Pharmaceuticals to co-host KOL on atopic dermatitis treatment
- ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
- Aslan Pharmaceuticals presents data from Phase 2b study of eblasakimab